WCM Investment Management
KROS icon

WCM Investment Management’s Keros Therapeutics KROS Stock Holding History

WCM Investment Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-113,860
Closed -$6.43M – 310
2024
Q3 		$6.43M Sell
113,860
-2,684
-2% -$133K 0.01% 161
2024
Q2 		$5.25M Sell
116,544
-486
-0.4% -$26.1K 0.01% 161
2024
Q1 		$7.75M Sell
117,030
-37,634
-24% -$2.23M 0.02% 149
2023
Q4 		$6.35M Buy
154,664
+57,122
+59% +$1.79M 0.02% 156
2023
Q3 		$3.11M Buy
97,542
+2,329
+2% +$86.9K 0.01% 169
2023
Q2 		$3.8M Buy
95,213
+11,187
+13% +$490K 0.01% 169
2023
Q1 		$3.59M Buy
84,026
+885
+1% +$44.7K 0.01% 168
2022
Q4 		$3.99M Buy
+83,141
New +$3.88M 0.01% 166

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WCM Investment Management's KROS Position: Q4 2024 in Review

WCM Investment Management sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 113,860 shares — an estimated $6.43M sold.

WCM Investment Management first reported a position in KROS in Q4 2022 and held it in 8 quarters. The position peaked at $7.75M in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • WCM Investment Management reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • WCM Investment Management sold 113,860 Keros Therapeutics shares in Q4 2024, an estimated $6.43M.
  • WCM Investment Management first reported a position in Keros Therapeutics in Q4 2022 and held it in 8 quarters.
  • WCM Investment Management's Keros Therapeutics position peaked at $7.75M in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on WCM Investment Management's 13F filing for Q4 2024, filed 28 Jan 2025.